Gilead Sciences (GILD -0.4%) and collaboration partner Galapagos NV (GLPG) announce that the European Medicines Agency (EMA) has accepted for review their marketing application for JAK1 inhibitor filgotinib for rheumatoid arthritis.
Under their amended partnership agreement, the companies will co-commercialize the product in France, Germany, Italy, Spain and the UK while GLGP will retain exclusive rights in Belgium, the Netherlands and Luxembourg. Future development costs will be equally shared.
GILD expects to file a U.S. marketing application by year-end.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.